Latest Kaiser Health News Stories
No private firms bid on the $30 million contract to set up and operate the state’s plan to bring in cheaper drugs. The setback is likely to delay by at least several months Florida’s effort to become the first state to import drugs under new federal regulations.
The progressive Change Now PAC launched a campaign ad, which also circulated on Facebook, criticizing President Donald Trump and Sen. Thom Tillis (R-N.C.) for not “fighting” for people with diabetes who struggle with the high cost of insulin.
President Donald Trump has been heralding drugmakers as “great companies.” Yet in the final stretch of the presidential campaign, Trump is not feeling the love in pharma contributions. Former Vice President Joe Biden is, even though his proposed policies could dent the industry’s profitability.
Approval of a vaccine will be an important step in defeating COVID-19. But it won’t immediately end the pandemic.
The CEO of Mallinckrodt Pharmaceuticals defended the price hikes of Acthar gel, an orphan drug that treats infantile spasms at a House Oversight Committee hearing on Thursday.
How will health issues affect voter choices? What will happen if President Donald Trump is reelected or the White House goes to Joe Biden? In this special election preview episode, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
Gov. Gavin Newsom approved many consequential health care bills by his bill-signing deadline Wednesday, including a ban on the sale of menthol and other flavored tobacco products, the creation of a state generic drug label and better coverage for mental health disorders.
Democrats on the House Oversight Committee released a damning investigation Wednesday of drug company pricing tactics and profits, as two days of hearings with testimony from pharmaceutical industry CEOs begin.
The president entered office seeking to overturn the Affordable Care Act, revamp Medicaid and drive down prescription drug prices, among other things. He’s hit some stone walls.
The announcement clears the way for Florida and other states to implement a program bringing medications across the border to save money. The effort is strongly opposed by drugmakers and the Canadian government.
The death of Supreme Court Justice Ruth Bader Ginsburg is giving new life to the latest constitutional challenge to the Affordable Care Act. It also places anti-abortion activists on the cusp of a court majority large enough to ensure the rollback of the right to abortion and, possibly, some types of birth control. Meanwhile, Health and Human Services Secretary Alex Azar tries to centralize power at the sprawling department plagued by miscommunications and scandals. Anna Edney of Bloomberg News, Kimberly Leonard of Business Insider and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Sarah Jane Tribble about her new podcast, “Where It Hurts,” debuting Sept. 29.
Data and safety monitoring boards work under a cloak of secrecy meant to prevent undue influence by stakeholders, such as companies or the government. In the Trump era, some worry the anonymity could actually invite it.
While insulin is the poster child for outrageous prescription costs, patients are paying ever more to treat depression, asthma, HIV, cholesterol and more. And the pandemic has overtaken efforts to force the issue in Congress.
President Donald Trump has the legal power to authorize a COVID vaccine over the objections of the Food and Drug Administration and vaccine manufacturers. Such a move could further erode public trust in a vaccine and foist an unsafe shot on Americans.
The Trump administration is primed to approve a plan designed to help lower costs of some prescription drugs by allowing states to import them from Canada. The announcement could come before Election Day, and Florida appears to be in line to go first.
President Donald Trump this week issued a prescription drug pricing order unlikely to lower drug prices, and he contradicted comments by his director of the Centers for Disease Control and Prevention on the need for mask-wearing and predictions for vaccine availability. Meanwhile, scandals erupted at the CDC, the Centers for Medicare & Medicaid Services and the Food and Drug Administration. And the number of people without health insurance grew in 2019, reported the Census Bureau, even while the economy soared. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
The National Institutes of Health has suggested minorities should be overrepresented in COVID-19 vaccine trials — perhaps at rates that are double their percentage of the U.S. population. But efforts to recruit patients from racial minority groups are just beginning, while some trials have already advanced to phase 3.
The AstraZeneca trial is on hold in the U.S. as scientists try to unravel whether a rare neurological condition is linked to the vaccine. But regulators are frustrated by a lack of information from the drugmaker.
The nation’s top infectious disease official is confident that an independent panel will base vaccine approval on science, not politics.
California could become the first state to develop its own line of generic drugs under a bill approved Monday by the legislature. The measure heads to Gov. Gavin Newsom for consideration.